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ABSTRACT
Introduction: Ceftolozane/tazobactam is an
antibacterial agent with potent in vitro
activity against Gram-negative pathogens,
including many extended-spectrum
b-lactamase-producing Enterobacteriaceae and
drug-resistant Pseudomonas aeruginosa. Because
ceftolozane/tazobactam is primarily excreted
renally, appropriate dose adjustments are
needed for patients with renal impairment.
Monte Carlo simulations were used to
determine the probability of pharmacokinetic/
pharmacodynamic target attainment for
patients with varying degrees of renal
function, including augmented renal clearance
(ARC) and end-stage renal disease (ESRD) with
hemodialysis.
Methods: Monte Carlo simulations were
conducted for 1000 patients with ARC and
normal renal function, mild renal impairment,
moderate renal impairment, or severe renal
impairment, and for 5000 patients with ESRD.
Simulated dosing regimens were based on
approved doses for each renal function
category. Attainment targets for ceftolozane
were 24.8% (bacteriostasis), 32.2% (1-log kill;
bactericidal), and 40% (2-log kill)
fT[minimum inhibitory concentration (MIC).
The target for tazobactam was to achieve a 20%
fT[minimum effective concentration (MEC) at
an MEC of 1 mg/L, which was derived from a
neutropenic mouse thigh infection model and
was confirmed by efficacy data from clinical
studies for complicated intraabdominal
infections and complicated urinary tract
infections.
Results: In patients with ARC or normal renal
function, C91% achieved bactericidal activity
(32.2% fT[MIC) up to an MIC of 4 mg/L
with a 1000-mg ceftolozane dose. In patients
with renal impairment (mild, moderate,
severe, ESRD), C93% achieved bactericidal
activity up to an MIC of 8 mg/L. In patients
of all renal function categories, the approved
dosing regimens of tazobactam achieved
C91% target attainment against a target of
20% fT[MEC.
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Conclusions: At the approved dosing regimens
for ceftolozane/tazobactam, C91% of patients
in all renal function categories, including ARC
(up to 200 mL/min) and ESRD, reached target
attainment for bactericidal activity at MICs that
correspond to susceptibility breakpoints for
Enterobacteriaceae and P. aeruginosa.
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INTRODUCTION
Ceftolozane/tazobactam is an antibacterial
agent that shows potent in vitro activity
against many extended-spectrum b-lactamase
(ESBL)-producing Enterobacteriaceae and
drug-resistant Pseudomonas aeruginosa,
including multidrug-resistant and extremely
drug-resistant isolates [1–3].
Ceftolozane/tazobactam is approved for the
treatment of complicated intraabdominal
infections (cIAI) when used in combination
with metronidazole and for complicated
urinary tract infections (cUTI), including
pyelonephritis [4].
In pharmacokinetic (PK) studies,
ceftolozane/tazobactam demonstrated
dose-dependent, linear PK with no clinically
relevant drug accumulation with standard
every-8-h dosing [4, 5]. Because
ceftolozane/tazobactam is eliminated primarily
by the kidneys, dosages must be adjusted to
account for impaired renal function, specifically
for patients with creatinine clearance (CrCl)
B50 mL/min [4, 6]. The primary objective of
this analysis was to simulate the probability of
PK/pharmacodynamic (PD) target attainment of
ceftolozane/tazobactam in patients with
varying degrees of renal impairment, including
augmented renal clearance (ARC) and end-stage
renal disease (ESRD).
METHODS
Population PK Model for Simulation
In the current analysis, PK/PD target attainment
for ARC, normal renal function, and mild,
moderate, or severe renal impairment was
simulated based on a previously developed
population PK model in which CrCl was a
significant covariate [7]. The model was
developed with the data from ten clinical
studies (eight phase 1 and two phase 2 studies)
in healthy subjects with normal renal function,
subjects with mildly impaired, moderately
impaired, or severely impaired renal function,
and patients with cUTI or cIAI [7]. These data
included the plasma concentrations of
ceftolozane and tazobactam that were
collected following intravenous administration
of ceftolozane/tazobactam, ceftolozane alone,
or tazobactam alone. A two-compartment
disposition model with zero-order input and
first-order elimination best characterized the
plasma concentration–time data for both
ceftolozane and tazobactam [7].
PK/PD target attainment for ESRD was
simulated based on a previously described
population PK model [8]. This model was
developed from a PK study in six subjects with
ESRD undergoing high-flux hemodialysis (HD)
with either Revaclear (Gambro, Stockholm,
Sweden) or CT 190G (Baxter Healthcare,
McGaw Park, IL, USA) hemodialyzers, and a
target adequacy (Kt/V) of at least 1.2 for a
minimum of 3 months before enrollment [6].
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Subjects were administered a single dose of
ceftolozane/tazobactam without HD (i.e.,
ceftolozane/tazobactam immediately after
HD), followed by a washout period with PK
sampling, and then a second dose administered
2 h before a 4-h HD, with intensive PK sampling
before and after HD. The collected PK data was
then fitted with a nonlinear mixed-effects
model with Phoenix NLME software, v.1.2
(Certara L.P. Pharsight, St. Louis, MO, USA).
This population PK model is also a
two-compartment disposition model to
describe the ceftolozane or tazobactam plasma
concentration–time data without HD and HD
was included as a covariate effect on both
clearance and volume of distribution for the
central compartment [8].
Monte Carlo Simulation
Monte Carlo simulations using the population
PK models were performed for 1000 patients in
each renal function category; 5000 patients
were simulated for ESRD. The renal function
categories included ARC (CrCl, [150 to
B200 mL/min), normal renal function (CrCl,
[90 to B150 mL/min), mild renal impairment
(CrCl, [50 to B90 mL/min), moderate renal
impairment (CrCl, C29 to B50 mL/min), severe
renal impairment (CrCl, C15 to\29 mL/min),
and ESRD (CrCl,\15 mL/min). These categories
of renal impairment were defined before the US
Food and Drug Administration (FDA) updated
guidance in 2010 [9], which redefined the cutoff
for moderate renal impairment to 30–59 mL/
min, and were retained for consistency of
category definitions across trials in the
ceftolozane/tazobactam clinical development
program. A separate analysis (included in the
New Drug Application submission but not
shown here) confirmed that definition of renal
impairment categories based on the updated
guidance would not change the conclusions. In
each simulation, except for ESRD, body weight
was sampled from a log-normal distribution in
the form of 74 9 exp[N(0, 0.2052)] kg, where
N(0, 0.2052) stands for a normal distribution at
a mean of 0 with a standard error of 0.205. This
was representative of patients included in the
phase 1 and phase 2 clinical trials. In
simulations for ESRD, body weight was not
relevant because it was not included in the PK
model.
Simulated intravenous dosing regimens,
administered over 1 h every 8 h, were based on
renal function category and FDA-approved
doses [4]: 1.5 g (1000/500 mg)
ceftolozane/tazobactam in patients with ARC,
normal renal function, or mild renal
impairment; 750 mg (500/250 mg)
ceftolozane/tazobactam in patients with
moderate renal impairment; 375 mg (250/
125 mg) ceftolozane/tazobactam in patients
with severe renal impairment; and 750 mg
(500/250 mg) ceftolozane/tazobactam loading
dose followed by maintenance dose of 150 mg
(100/50 mg) ceftolozane/tazobactam over 1 h
every 8 h for ESRD. Multiple dialysis scenarios
were tested for ESRD; we report here the
representative weekly scheme of a 4-h HD on
Monday, Wednesday, and Friday (i.e.,
HD? 2 days? HD? 2 days? HD? 3 days).
A dose was administered immediately following
each HD, and the single loading dose was used
for the first dose only. Up to 2 cycles (14 days)
were simulated for each case, and daily target
attainment on day 3 (after the second HD) was
the lowest and was reported as a conservative
approach.
A finite element method with a time step of
0.001 h was used to simulate the total
concentration–time profiles based on the
following mass balance differential equations
for the population PK model:
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dXc=dt ¼ Rt Cl þ Q2ð Þ =VcXc þ Q2=V2X2
dX2=dt ¼ Q2=VcXc  Q2=V2X2
where Xc and X2 represent the amount of the
drug at time t in the central compartment and
peripheral compartment, respectively; Rt
represents the infusion rate at time t; Cl and
Q2 represent the terminal clearance and
intercompartmental clearance between the
central and peripheral compartments,
respectively; and Vc and V2 represent the
volume of distribution for the central and
peripheral compartments, respectively. The
population PK model parameter estimates were
from the previously published population PK
models [7, 8, 10]. To explore the situations in
which exposures may be lower in some patients
than in typical patients or healthy volunteers at
the same dose, however, patients with cIAI were
assumed for the simulations. This patient group
was selected because it was observed that PK
exposure in cIAI patients was lower than in
non-cIAI subjects (i.e., cUTI patients or healthy
volunteers) [7]. In addition, interindividual
variability for the parameter estimates in the
PK models was conservatively inflated to have a
50% coefficient of variation in the log-scale to
cover potentially larger variability in real
patients.
PK/PD target attainment by minimum
inhibitory concentration (MIC) was assessed
for ceftolozane by nonclinical PK/PD targets
for simulated patients in each renal function
category. As with other cephalosporins, the
percentage of time with free drug
concentration above the MIC (%fT[MIC) was
the PD driver for ceftolozane [11]. The targets
for ceftolozane were 24.8% (bacteriostatic),
32.2% (for 1-log kill; bactericidal), and 40%
(2-log kill), representing the median %fT[MIC
associated with these levels of activity against
Enterobacteriaceae and P. aeruginosa in the
neutropenic mouse model [10–13]. The
percentage of simulated patients who attained
these targets during the dosing interval at
steady state for MIC values ranging from 0.03
to C32 mg/L was determined for each dosing
regimen evaluated within each renal function
category. The current Clinical and Laboratory
Standards Institute (CLSI) [14] susceptibility
breakpoints, which are consistent with the
FDA breakpoints, for ceftolozane/tazobactam
are 2 mg/L for Enterobacteriaceae and 4 mg/L
for P. aeruginosa.
The target with tazobactam was to achieve
20% of time above minimum effective
concentration (MEC; 20% fT[MEC) of 1 mg/L
to effectively inhibit b-lactamases. The rationale
for using the 1 mg/L tazobactam threshold is
based on several in vitro and in vivo studies.
In vitro enzyme-binding studies demonstrated
that the concentration of b-lactamase inhibitor
required to reduce b-lactamase enzyme activity
by 50% (IC50) is less than 0.3 mg/L for[97% of
the b-lactamases tested (n = 35) and for all class
A b-lactamase-producing strains (n = 12)
[15–17]. Consistent with the IC50 values from
these in vitro enzyme-binding experiments, the
tazobactam threshold value was determined to
be B1 mg/L across in vitro dose fractionation
and in vivo neutropenic mouse thigh infection
PD experiments [11, 18]. Additionally,\1 mg/L
was found to be fully effective against all ten
clinical strains tested [Escherichia coli (n = 6) and
Klebsiella pneumoniae (n = 4)] in a mouse thigh
neutropenic model in which a geometrically
averaged 20% fT[threshold of 1 mg/L
tazobactam was observed to be efficacious
(data on file). Based on exposure–response
relationships determined in the neutropenic
murine thigh model for ceftolozane combined
with tazobactam, the efficacy target for
tazobactam for the fT[threshold
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concentration of 1 mg/L was estimated to be a
geometric mean of 19.5% (mean 25.2%; median
21%; range 6.6–51.9%) (internal data). As
conceptually illustrated in Fig. 1, based on the
typical tazobactam concentration–time profile
following administration of 90 mg tazobactam
in cIAI patients with normal renal function, the
target of 20% fT[MEC of 1 mg/L is equivalent
to the target of 80% fT[threshold of 0.05 mg/
mL, which is slightly higher than the target of
70% fT[threshold of 0.05 mg/L for 2-log kill
against isolates with low and moderate
b-lactamase genetic constructs [18], and
equivalent to the target of 50% fT[threshold
of 0.25 mg/L for 1-log kill against isolates with
high b-lactamase genetic constructs [18]. In
other words, the target of 20% fT[MEC of
1 mg/L, although derived from the neutropenic
mouse thigh infection model, is consistent with
and even more strict numerically than other
observed in vitro and in vivo targets, such that a
dose achieving this target will also achieve the
other published targets at least for 1-log kill
against even the toughest tested
b-lactamase-producing isolates. This is
especially true in patients with renal
impairment in whom MIC-time profiles
display longer half-lives, making it more
difficult to achieve a target at a higher
concentration threshold than an equivalent
target at a lower MIC threshold.
Against non-ESBL-producing pathogens such
as P. aeruginosa, only target attainment of
ceftolozane is relevant and is thus used for
dose selection; however, against
ESBL-producing pathogens such as
Enterobacteriaceae, it is essential to achieve
high target attainment for both ceftolozane
and tazobactam simultaneously.
In calculations of %fT[MIC for ceftolozane
and %fT[MEC for tazobactam, unbound
fractions (fu) of 0.79 and 0.70 were used [10]
for the simulated total concentration–time
profiles for ceftolozane and tazobactam,
respectively.
Statistical analyses and simulations were
performed using SAS 9.2 or 9.3 (SAS Institute
Inc, NC, USA).
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
Data Availability
The data sets generated and analyzed during the
current study are available from the
corresponding author on reasonable request.
Fig. 1 Typical tazobactam concentration–time proﬁle
(after a 1-h infusion of 90 mg tazobactam in patients
with cIAI and normal renal function), showing consistency
across different target/threshold settings: 20% fT[MEC
of 1 mg/L is equivalent to 50% fT[threshold of 0.25 mg/
L and 80% fT[threshold of 0.05 mg/L. The targets are
achieved in 50% of patients at a dose of 90 mg and can be
achieved in C97% patients at the approved dose of 500 mg
(covering variability). cIAI intraabdominal infection,
fT [MEC free-drug time above MEC, MEC minimum
effective concentration
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RESULTS
PK/PD Target Attainment for Ceftolozane
Systemic exposure to ceftolozane and
tazobactam at the approved doses, as reflected
by maximum plasma drug concentration (Cmax)
and area under the concentration–time curve
extrapolated to infinity (AUC0–?), are presented
in Tables 1 and 2, respectively. Only observed
Cmax and AUC values are reported in the tables;
no simulated values. Because no PK data were
available from patients with ARC in the clinical
trials, no observed values for Cmax or AUC are
available for those patients.
The most recent surveillance data for
ceftolozane/tazobactam (2015) demonstrated
that MIC50/90 values for isolates from the
United States and the European Union,
respectively, were 0.5/1 and 0.5/16 mg/L for P.
aeruginosa and 0.25/1 and 0.25/2 mg/L for
Enterobacteriaceae [19; data on file]. Monte
Carlo simulation results showed that the
percentage of simulated patients achieving
%fT[MIC targets increased as the MIC value
or the magnitude of the target decreased. Up to
an MIC of 8 mg/L, C93% of patients across all
renal function impairment categories (mild,
moderate, severe, ESRD) achieved the target
for bactericidal activity (i.e., 32.2% fT[MIC)
(Table 1; Fig. 2a, b).
In the ARC category at the 1.5-g
ceftolozane/tazobactam dose, C91% of
patients achieved 32.2% fT[MIC up to 4 mg/
L. Among patients with normal and mild renal
impairment, the 32.2% fT[MIC target was
achieved with 1.5 g ceftolozane/tazobactam in
C96% of patients at MICs up to 4 mg/L. At the
corresponding adjusted doses, C99% of patients
with moderate to severe renal impairment
achieved the 32.2% fT[MIC targets at MICs
up to 4 mg/L. In patients with ESRD, a regimen
of 750-mg ceftolozane/tazobactam loading dose
followed by 150-mg maintenance dose resulted
in 100% target attainment for up to 40%
fT[MIC targets at MICs up to 4 mg/L on all
days (Table 1).
PK/PD Target Attainment for Tazobactam
In patients with normal renal function at the
1.5-g ceftolozane/tazobactam dose, the
estimated probability of target attainment for
tazobactam at the 20% fT[MEC target was 97%
for an MEC of 1 mg/L. Among patients with
ARC, C91% achieved tazobactam 20% fT[MEC
target attainment (Table 2; Fig. 3).
For the mild, moderate, and severe categories
of renal impairment, C99% of patients achieved
the 20% fT[MEC target at the recommended
ceftolozane/tazobactam dosing regimen.
For ESRD, the predicted target attainment for
tazobactam at the 20% fT[MEC target was
C94% on all days of the recommended dosing
regimen.
DISCUSSION
Because ceftolozane/tazobactam is renally
excreted, renal function is a significant factor
influencing PK, with drug clearance decreasing
substantially with increasing renal impairment
[7]. Appropriate creatinine measurements that
can accurately reflect renal function are critical
for dose adjustment, especially at the initial
doses. If the baseline creatinine measurement is
low, dose adjustment may lead to suboptimal
exposure and poor treatment outcome.
Therefore, supporting clinical markers to
confirm actual renal impairment (compared
with normal renal function) should be
considered before a patient receives a reduced
dose.
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As is the case with other cephalosporins, the
efficacy of ceftolozane/tazobactam is best
correlated with %fT[MIC [11]. Using Monte
Carlo simulations, we showed that the
probability of target attainment in the most
conservative case is estimated to be C91% for
1-log kill and C82% for 2-log kill bactericidal
activity in patients with ARC or mild, moderate,
or severe renal impairment, and in ESRD
patients at the recommended dosing regimens
at MICs up to 2 and 4 mg/L, corresponding to
the current Enterobacteriaceae and P. aeruginosa
breakpoints, respectively. Monte Carlo
simulation of tazobactam showed that C91%
of patients achieved the target of 20% fT[MEC
of 1 mg/L for all renal function categories.
Although PK/PD target attainment for
tazobactam was not used for dose
optimization for the other categories of renal
impairment, it was the driver for dose
optimization in ESRD patients because the
elimination pathway through metabolism
(20% in healthy volunteers with normal renal
function) [4, 5] became more important than
renal clearance in this group of patients.
In general, the achieved high target
attainment for the primary targets for both
ceftolozane (C32.2% fT[MIC) and tazobactam
(C20% fT[MEC of 1 mg/L) at the approved
doses was consistent with the high clinical
success rate from the phase 3 ASPECT-cUTI
and -cIAI trials [20, 21], suggesting the validity
of the targets.
This study had various limitations. First,
although MICs of ceftolozane/tazobactam were
determined in the presence of 4 mg/L
tazobactam, as recommended by the CLSI [22],
PTA estimates for ceftolozane were based solely
on ceftolozane, an approach that has validity
for non-ESBL-producing pathogens in patients.
Table 2 Summary of the observed Cmax and AUC0-? after a single dose and simulated probability of tazobactam target









PTA ‡20% fT > MECb
MEC 5 1 mg/mL
ARC ([150 to B200) 1000/500 NA NA 91
Normal ([90 to B150) 1000/500 17.0 (14.7–31.4) 30.1 (21.7–40.4) 97
Mild impairment ([50 to B90) 1000/500 21.9 (18.9–28.3) 34.7 (29.1–43.4) 100
Moderate impairment
(C29 to B50)
500/250 27.1 (23.3–28.7) 65.9 (49.1–91.9) 100
Severe impairment (C15 to\29) 250/125 16.3 (10.2–18.3) 56.5 (35.8–70.9) 99
ESRD with hemodialysis 500/250; 100/50a 14.9 (7.2–22.9)b 40.3 (23.3–58.6)b 94c
No PK data were available from patients with ARC in the clinical trials, thus, no observed values for Cmax or AUC are
available for those patients
ARC augmented renal clearance, AUC0–? area under the concentration–time curve extrapolated to inﬁnity, Cmax
maximum concentration, CrCl creatinine clearance, ESRD end-stage renal disease, fT[MEC free-drug time above MEC,
MEC minimum effective concentration, NA not applicable, PTA probability of target attainment, TOL/TAZ
ceftolozane/tazobactam
a 500/250 mg loading dose followed by 100/50 mg maintenance doses
b Measurements taken on hemodialysis and with 500/250 mg dose
c Steady state for non-ESRD patients and lowest value on the day immediately after hemodialysis for ESRD/hemodialysis
patients
144 Infect Dis Ther (2017) 6:137–148
For ESBL-producing pathogens, published data
support tazobactam as an inhibitor of
b-lactamase activity and indicate that the PD
driver for tazobactam is the percentage of time
above a threshold concentration
(%fT[threshold) [23]. Given that our data
suggest that the highest tazobactam threshold
was 1 mg/L against ESBL-producing pathogens,
under the condition of high attainment for this
target, PTA calculations using ceftolozane alone
appear to be a practical and reasonable
approach. PTA calculations based on the
combination of ceftolozane and tazobactam
are mechanistically interesting, but the
methodology on the optimal way to model
two components (a cephalosporin and a
b-lactamase inhibitor) simultaneously is still
under discussion, and several potential
approaches have been proposed [24–27].
Nevertheless, the individual exposure of
ceftolozane (%fT[MIC) and tazobactam
(%fT[MEC) in patients with normal function
is high at the 1.5-g dose and was confirmed to
be efficacious in clinical trials for cUTIs and
cIAIs against both non-ESBL-producing and
ESBL-producing pathogens [20, 21]. Second,
this study was limited by the lack of clinical
data to support the findings in ARC, severe renal
impairment, and ESRD. Recent case studies,
however, have reported successful clinical
Fig. 2 Simulated ceftolozane PK/PD target attainment
[32.2% fT[MIC target (1-log kill)] at steady state by
renal function group across MIC values following
administration of the approved dose regimens. Histograms
show MIC distributions for 2015 surveillance isolates [19;
data on ﬁle]. a P. aeruginosa [MIC90, 1 mg/L (United
States), 16 mg/L (European Union)]. b Enterobacteriaceae
[MIC90, 1 mg/L (United States), 2 mg/L (European
Union)]. CrCl creatinine clearance, ESRD end-stage renal
disease, HD hemodialysis, MIC minimum inhibitory
concentration, PD pharmacodynamics, PK
pharmacokinetics
Fig. 3 Simulated tazobactam PK/PD target attainment
(20% fT[MEC) at steady state by renal function group
acrossMEC values following administration of the approved
dose regimens. CrCl creatinine clearance, ESRD end-stage
renal disease, fT[MEC free-drug time above MEC, HD
hemodialysis, MEC minimum effective concentration, PD
pharmacodynamics, PK pharmacokinetics
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outcomes in patients with more severe renal
impairment [28, 29]. Third, this study was based
on population PK models and simulations with
characteristics from patients not critically ill,
though still infected, or from patients with
ESRD who were otherwise healthy. In contrast,
many critically ill patients have lower drug
clearances, larger volumes of distribution, and,
consequently, longer terminal half-lives than
healthy persons. These factors are to be
confirmed by the ongoing study in critically ill
patients (ClinicalTrials.gov, NCT02387372).
Finally, this study does not include the case
for patients with ARC higher than 200 mL/min
or the case for tissue infection in which
penetration of the drug into the infected tissue
site might be low (for example, penetration into
lung tissue in patients with pneumonia). In
both cases, a higher dose might be necessary.
Indeed, a higher dose of 3 g
ceftolozane/tazobactam has been well
tolerated in PK studies [10, 30] and is being




This analysis confirms that the approved dosing
regimens for ceftolozane/tazobactam in
patients with mild, moderate, or severe renal
impairment and in patients with ESRD are
sufficient to achieve high target attainment for
bactericidal activity at all the approved
breakpoints.
ACKNOWLEDGEMENTS
Sponsorship for this simulation study and
article processing funds were provided by
Merck & Co., Inc., Kenilworth, NJ, USA. All
authors had full access to all the data in this
study and take complete responsibility for the
integrity of the data and the accuracy of the
data analysis. Editorial assistance in the
preparation of this manuscript was provided
by Sally Mitchell, PhD, and Meher Dustoor,
PhD, of ApotheCom, Yardley, PA, USA. This
assistance was funded by Merck & Co., Inc.,
Kenilworth, NJ, USA. All named authors meet
the International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
manuscript, take responsibility for the integrity
of the work as a whole, and have given final
approval to the version to be published.
Disclosures. Alan J. Xiao was an employee of
Merck & Co., Inc., Kenilworth, NJ, USA, at the
time the data used in these analyses were
generated; he is now an employee of Novartis.
Luzelena Caro is an employee of Merck & Co.,
Inc., Kenilworth, NJ, USA. Myra W. Popejoy is
an employee of Merck & Co., Inc., Kenilworth,
NJ, USA. Jennifer A. Huntington is an employee
of Merck & Co., Inc., Kenilworth, NJ, USA.
Ravina Kullar is an employee of Merck & Co.,
Inc., Kenilworth, NJ, USA.
Compliance with Ethics Guidelines. This
article does not contain any new studies with
human or animal subjects performed by any of
the authors.
Data Availability. The data sets generated
and analyzed during the current study are
available from the corresponding author on
reasonable request.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommercial
146 Infect Dis Ther (2017) 6:137–148
use, distribution, and reproduction in any
medium, provided you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. Zhanel GG, Chung P, Adam H, et al.
Ceftolozane/tazobactam: a novel
cephalosporin/beta-lactamase inhibitor
combination with activity against
multidrug-resistant gram-negative bacilli. Drugs.
2014;74:31–51.
2. Farrell DJ, Sader HS, Flamm RK, Jones RN.
Ceftolozane/tazobactam activity tested against
Gram-negative bacterial isolates from hospitalised
patients with pneumonia in US and European
medical centres (2012). Int J Antimicrob Agents.
2014;43:533–9.
3. Farrell DJ, Flamm RK, Sader HS, Jones RN.
Antimicrobial activity of ceftolozane-tazobactam
tested against Enterobacteriaceae and Pseudomonas
aeruginosa with various resistance patterns isolated
in U.S. hospitals (2011–2012). Antimicrob Agents
Chemother. 2013;57:6305–10.
4. Zerbaxa (ceftolozane and tazobactam) [prescribing
information]. Whitehouse Station: Merck Sharp &
Dohme, 2015.
5. Miller B, Hershberger E, Benziger D, Trinh M,
Friedland I. Pharmacokinetics and safety of
intravenous ceftolozane-tazobactam in healthy
adult subjects following single and multiple
ascending doses. Antimicrob Agents Chemother.
2012;56:3086–91.
6. Wooley M, Miller B, Krishna G, Hershberger E,
Chandorkar G. Impact of renal function on the
pharmacokinetics and safety of
ceftolozane-tazobactam. Antimicrob Agents
Chemother. 2014;58:2249–55.
7. Chandorkar G, Xiao A, Mouksassi MS, Hershberger
E, Krishna G. Population pharmacokinetics of
ceftolozane/tazobactam in healthy volunteers,
subjects with varying degrees of renal function
and patients with bacterial infections. J Clin
Pharmacol. 2015;55:230–9.
8. Xiao A, Chandorkar G, Krishna G, Hershberger E.
Ceftolozane/tazobactam (C/T) dose optimization in
patients with end stage renal disease (ESRD)
requiring hemodialysis (HD) using population
pharmacokinetics (pPK) and Monte Carlo
simulations (MCS). Presented at: MAD-ID 18th
Annual Congress; May 7–9, 2015; Orlando.
9. US Department of Health and Human Services.
Guidance for industry: pharmacokinetics in
patients with impaired renal function—study
design, data analysis, and impact on dosing and
labeling (March 2010). Report No. 91. http://www.
fda.gov/downloads/Drugs/…/Guidances/UCM2049
59.pdf. Accessed October 25, 2016.
10. Xiao AJ, Miller BW, Huntington JA, Nicolau DP.
Ceftolozane/tazobactam pharmacokinetic/
pharmacodynamic derived dose justification for
phase 3 studies in patients with nosocomial
pneumonia. J Clin Pharmacol. 2015;56:56–66.
11. Craig WA, Andes DR. In vivo activities of
ceftolozane, a new cephalosporin, with and
without tazobactam against Pseudomonas
aeruginosa and Enterobacteriaceae, including
strains with extended-spectrum beta-lactamases,
in the thighs of neutropenic mice. Antimicrob
Agents Chemother. 2013;57:1577–82.
12. Drusano GL. Antimicrobial pharmacodynamics:
critical interactions of ‘bug and drug’. Nat Rev
Microbiol. 2004;2:289–300.
13. Lepak AJ, Reda A, Marchillo K, Van Hecker J, Craig
WA, Andes D. Impact of MIC range for Pseudomonas
aeruginosa and Streptococcus pneumoniae on the
ceftolozane in vivo pharmacokinetic/
pharmacodynamic target. Antimicrob Agents
Chemother. 2014;58:6311–4.
14. Clinical and Laboratory Standards Institute.
M100-S26 performance standards for antimicrobial
susceptibility testing: twenty-sixth edition. Wayne:
CLSI; 2016.
15. Payne DJ, Cramp R, Winstanley DJ, Knowles DJ.
Comparative activities of clavulanic acid,
sulbactam, and tazobactam against clinically
important beta-lactamases. Antimicrob Agents
Chemother. 1994;38:767–72.
16. Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang
Y. Kinetic interactions of tazobactam with
beta-lactamases from all major structural classes.
Antimicrob Agents Chemother. 1993;37:851–8.
17. Naumovski L, Quinn JP, Miyashiro D, et al.
Outbreak of ceftazidime resistance due to a novel
extended-spectrum beta-lactamase in isolates from
cancer patients. Antimicrob Agents Chemother.
1992;36:1991–6.
18. Vanscoy B, Mendes RE, Nicasio AM, et al.
Pharmacokinetics-pharmacodynamics of
Infect Dis Ther (2017) 6:137–148 147
tazobactam in combination with ceftolozane in an
in vitro infection model. Antimicrob Agents
Chemother. 2013;57:2809–14.
19. Huband MD, Flamm RK, Jones RN, Sader HS, Farrell
DJ. In vitro activity of ceftolozane/tazobactam
against pseudomonas aeruginosa and
enterobacteriaceae isolates collected from medical
centers in the USA (2015) 2015. Presented at:
American Society for Microbiology (ASM) Microbe
2016; June 16–20, 2016; Boston, MA. Poster 431.
20. Solomkin J, Hershberger E, Miller B, et al.
Ceftolozane/tazobactam plus metronidazole for
complicated intra-abdominal infections in an era
of multidrug resistance: results from a randomized,
double-blind, phase 3 trial (ASPECT-cIAI). Clin
Infect Dis. 2015;60:1462–71.
21. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G,
Darouiche RO. Ceftolozane-tazobactam compared
with levofloxacin in the treatment of complicated
urinary-tract infections, including pyelonephritis: a
randomised, double-blind, phase 3 trial
(ASPECT-cUTI). Lancet. 2015;385:1949–56.
22. Clinical Laboratory Standards Institute. Methods
for dilution antimicrobial susceptibility tests for
bacteria that grow aerobically: report no. M07-A09;
ninth edition. Wayne: CLSI, 2012.
23. Vanscoy B, Mendes RE, Castanheira M, et al.
Relationship between ceftolozane-tazobactam
exposure and drug resistance amplification in a
hollow-fiber infection model. Antimicrob Agents
Chemother. 2013;57:4134–8.
24. Bhagunde P, Chang KT, Hirsch EB, Ledesma KR,
Nikolaou M, Tam VH. Novel modeling framework
to guide design of optimal dosing strategies for
beta-lactamase inhibitors. Antimicrob Agents
Chemother. 2012;56:2237–40.
25. Rubino C, Bhavnani SM, Steenbergen JN,
Krishna G, Ambrose PG.
Pharmacokinetic-pharmacodynamic (PK-PD) target
attainment analyses supporting the selection of
in vitro susceptibility test interpretive criteria for
ceftolozane/tazobactam (TOL/TAZ) against
Enterobacteriaceae. Presented at: 54th Annual
Interscience Conference on Antimicrobial Agents
and Chemotherapy; September 5–9, 2014;
Washington, DC. Poster A-1347.
26. Melchers MJ, Mavridou E, Seyedmousavi S, van Mil
AC, Lagarde C, Mouton JW. Plasma and ELF
pharmacokinetics of ceftolozane and tazobactam
alone and in combination in mice. Antimicrob
Agents Chemother. 2015;59:3373–6.
27. European Medicines Agency. Guidelines on the use
of pharmacokinetics and pharmacodynamics in the
development of antimicrobial medicinal products.
http://www.ema.europa.eu/docs/en_GB/document_
library/Scientific_guideline/2016/07/WC500210982.
pdf. Accessed 25 Oct 2016.
28. Bremmer DN, Nicolau DP, Burcham P, Chunduri A,
Shidham G, Bauer KA. Ceftolozane/tazobactam
pharmacokinetics in a critically ill adult receiving
continuous renal replacement therapy.
Pharmacotherapy. 2016;36:e30–3.
29. Patel UC, Nicolau DP, Sabzwari RK. Successful
treatment of multi-drug resistant Pseudomonas
aeruginosa bacteremia with the recommended
renally adjusted ceftolozane/tazobactam regimen.
Infect Dis Ther. 2016;5:73–9.
30. Miller B, Chandorkar G, Umeh O, Friedland I,
Hershberger E. Safety and pharmacokinetics (PK) of
intravenous (IV) ceftolozane/tazobactam (C/T)
every 8 hours (18 h) and cumulative fraction of
response (CFR) in plasma and epithelial lining fluid
(ELF) in a simulated ventilator-associated
pneumonia (VAP) population. Presented at: 52nd
Interscience Conference on Antimicrobial Agents
and Chemotherapy, September 9–12, 2012; San
Francisco, CA.
148 Infect Dis Ther (2017) 6:137–148
